Analysts think CLSD stock price could increase by 347%
Aug 01, 2024, 6:25 AM
-10.96%
What does CLSD do
Clearside Biomedical, Inc., headquartered in Alpharetta, Georgia, specializes in delivering therapies to the back of the eye using a unique suprachoroidal space (SCS) injection platform. The company, which went public in 2016, is developing products like XIPERE and collaborates with partners on other ophthalmic therapies using its SCS Microinjector.
9 analysts think CLSD stock price will increase by 347.37%. The current median analyst target is $5.10 compared to a current stock price of $1.14. The lowest analysts target is $4.04 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
